Add BrightSurf on Google Email

Video-assisted informed consent helps reduce decisional conflict in cancer patients

A study by Fujita Health University found that watching a patient education video about surgery before consultation can reduce uncertainty and shorten doctor–patient discussion. The results showed a 40% reduction in consultation time, and a lower decisional conflict score in the video group.

SourceFujita Health University·JournalWorld Journal of Gastrointestinal Surgery·TypeRandomized controlled/clinical trial·DateNov 10, 2026

In Mass General Brigham-led phase 2 trial, novel therapy significantly reduced triglyceride levels

A phase 2b clinical trial led by Mass General Brigham researchers shows that MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. The therapy targets ANGPTL4, a protein that naturally inhibits lipoprotein lipase, an enzyme that breaks down triglycerides.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 9, 2026

Wash U Medicine Cancer study professional recognized with Clinical Research Integrity Award by Alliance for Clinical Trials in Oncology

Jennifer Frederick, an oncology clinical trial organizer at Wash U Medicine, received the 2026 Alliance Clinical Research Professionals Research Integrity Service Award for her dedication to helping cancer patients access clinical trials. Her work ensures that trials run smoothly and safely, with a focus on patient advocacy and compass...

Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial

A global phase 3 clinical trial, ZEUS, tested a drug targeting interleukin-6, but found no reduction in cardiovascular event rates compared to placebo. The study's neutral findings suggest moving upstream to find the right target, while acknowledging the effectiveness of downstream IL-6 inhibition in modifiable earlier stage disease.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 7, 2026

Nature Medicine publication reveals how human movement predicts hidden biosignals spanning 18 body systems, from heart and liver function to metabolic and mental health

A study published in Nature Medicine reveals that artificial intelligence can identify associations between human movement patterns and 1,887 health measures spanning 18 body systems. Movement analysis provided independent predictive information beyond traditional health assessments.

SourceBrightPoint·JournalNature Medicine·TypeImaging analysis·DateNov 6, 2026

New digital therapy prevents anxiety increasing during pregnancy and after birth

A new digital therapy, RELAX, has shown significant reductions in pre- and post-birth anxiety, depression, and repetitive negative thinking in pregnant women. The study, led by King's College London, found that the therapy can prevent anxiety from escalating during pregnancy, improving maternal mental health outcomes.

SourceKing's College London·JournalJAMA Network Open·TypeRandomized controlled/clinical trial·DateNov 4, 2026

Anti-HIV antibody clinical trials offer clues to prevent viral escape and resistance

A new analysis of VRC01 clinical trial data reveals the antibody's initial strong protection against HIV, but some strains can cause breakthrough infections after treatment ends. The findings highlight the importance of combining multiple antibodies to suppress HIV completely and prevent breakthrough infections in vulnerable individuals.

SourceAmerican Association for the Advancement of Science (AAAS)·JournalScience Translational Medicine·DateNov 4, 2026

Could there be an alternative to dialysis?

A landmark trial found that older patients with kidney failure may benefit from a structured care approach without dialysis, offering an alternative to traditional treatment. The study, led by the University of Bristol, found that both approaches resulted in similar overall length and quality of life.

SourceUniversity of Bristol·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateNov 4, 2026

Little evidence that common workplace ergonomics help

A Cochrane review found that ergonomic interventions have no significant impact on pain, function, or sick leave for workers with work-related arm, neck, or shoulder complaints. The review of 20 trials involving 2,478 people found little to no difference between ergonomic interventions and no treatment in short-term pain relief.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateOct 27, 2026

Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026

Insilico Medicine announced promising Phase 1 data for ISM6331, a pan-TEAD inhibitor designed using generative AI, showing a 40.0% objective response rate at 130 mg once daily in heavily pretreated mesothelioma. The drug also demonstrated disease control in more than two-thirds of evaluable participants.

Gut microbiome may help explain why sleep improvement varies after hydrogen supplementation

Researchers found that hydrogen supplementation had no significant effect on sleep quality, but individuals with lower gut microbiome hydrogen production showed greater improvements. The study suggests that individual differences in gut microbiome may influence response to hydrogen supplementation.

SourceHiroshima University·JournalScientific Reports·TypeRandomized controlled/clinical trial·DateOct 23, 2026

Swim Across America-funded cancer research leads to landmark FDA approval of immunotherapy for rectal cancer

A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...

SourceSwim Across America·TypeRandomized controlled/clinical trial·DateOct 22, 2026

Three-week radiation course a safe option for breast cancer patients undergoing reconstruction, Alliance trial shows

A new trial shows that a shorter three-week radiation course is as safe and effective as the standard five-week treatment for women undergoing breast reconstruction. The RT CHARM trial found no increase in complications or effects on reconstruction efforts.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateOct 21, 2026

Scientists identify Id3 as a molecular brake that could enhance ultrasound-induced bone regeneration

Scientists have identified Id3 as a key molecular regulator of low-intensity pulsed ultrasound (LIPUS)-induced bone formation. An Id3 inhibitory peptide, rID3, combined with LIPUS, enhances osteogenesis and improves bone-defect healing in mice. The study provides a potential strategy for enhancing ultrasound-based bone regeneration.

SourceEditorial Office of West China School of Stomatology, Sichuan University·JournalInternational Journal of Oral Science·TypeExperimental study·DateOct 15, 2026

Small-molecule therapy for Alzheimer’s disease shows promise in mice and an early clinical trial

A new small molecule therapy targets the brain's microglia cells to protect neurons, reducing markers of neuronal damage and inflammatory signaling. The therapy, VG-3927, is well-tolerated and penetrates the central nervous system, reducing levels of a marker of TREM2 in patients with Alzheimer's disease.

SourceAmerican Association for the Advancement of Science (AAAS)·JournalScience Translational Medicine·DateOct 14, 2026

New device targets nerve signals to treat cancer-related wasting, moving to first human trial

A new device has been approved for a first human trial to treat cancer-related wasting, a severe and progressive syndrome affecting many patients with advanced cancer. The device, OnVagus, delivers noninvasive electrical stimulation to modulate the vagus nerve, aiming to preserve strength and quality of life during treatment.

SourceTerasaki Institute for Biomedical Innovation·TypeRandomized controlled/clinical trial·DateOct 7, 2026

Major HER2+ breast cancer trial identifies factors associated with pathologic complete response to less intensive chemotherapy

A significant proportion of patients with HER2-positive, ER-negative breast cancer can achieve a pathologic complete response after 12 weeks of THP chemotherapy. The trial identified ER-negative or low ER-expressing tumors, low or no progesterone receptor expression, HER2 IHC 3+ tumors, and weekly paclitaxel treatment as key predictors...

SourceECOG-ACRIN Cancer Research Group·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateOct 6, 2026

Cancer trial drug may work differently than scientists believed, raising concerns for clinical research

Researchers found that the cancer drug zavondemstat and a closely related compound QC6352 do not primarily target KDM4, but instead work by blocking DHODH, an enzyme cancer cells rely on to produce molecules needed for rapid growth. This discovery highlights a broader challenge in cancer drug development, emphasizing the need for great...

SourceUniversity of Sydney·JournalNature Chemical Biology·TypeExperimental study·DateOct 6, 2026

Alliance Foundation trials and Natera announce AFT-70 navigate: A global, randomized, phase iii trial evaluating genentech’s oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 inhibitor therapy in ER+/HER2− breast canc

The AFT-70 NAVIGATE trial tests a novel molecular residual disease-guided treatment strategy for ER-positive/HER2-negative breast cancer patients. The trial pairs giredestrant with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor.

Master protocol trials could reimagine the future of rare disease research

Researchers propose using master protocol trials to speed up the development of treatments for rare diseases, which affect fewer than 200,000 people in the US. By testing multiple drugs or conditions simultaneously, these trials aim to reduce costs and improve testing efficiency, ultimately bringing effective treatments to patients fas...

SourceKennedy Krieger Institute·JournalAnnals of Neurology·TypeData/statistical analysis·DateOct 5, 2026

Mount Sinai Tisch Cancer Center cuts clinical trial data-entry time by more than half with real-time EHR-to-EDC technology

The Mount Sinai Tisch Cancer Center has implemented a real-time EHR-to-EDC technology platform, reducing clinical trial data-entry time by over half and improving data accuracy. The platform automatically transfers 70% of data with 100% accuracy, freeing up research teams to focus on patient care and advancing research.

Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer

A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·DateSep 28, 2026

Five-treatment radiation therapy offers effective nonsurgical alternative for localized prostate cancer

A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...

Exocrine pancreatic insufficiency affects 40% of chronic pancreatitis patients

A systematic review and meta-analysis found that approximately 40% of patients with chronic pancreatitis worldwide develop exocrine pancreatic insufficiency, a condition that can lead to malabsorption, weight loss, and deficiencies in fat-soluble vitamins. Smoking emerged as a significant modifiable risk factor, emphasizing the need fo...

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalJournal of Pancreatology·TypeSystematic review·DateSep 28, 2026

ECOG-ACRIN launches a landmark trial to evaluate chemotherapy benefit in high-risk early-stage breast cancer

A new trial will determine whether chemotherapy provides additional benefit for patients with high anatomic risk but low genomic risk. The RxFINE-Low trial will enroll 2,000 postmenopausal women and men with high anatomic risk breast cancer and low genomic risk, and follow them for up to 10 years.

SourceECOG-ACRIN Cancer Research Group·TypeRandomized controlled/clinical trial·DateSep 24, 2026

New Trinity research suggests a simple pill could prevent sight loss in common form of diabetes-driven eye condition

Researchers have found that an oral medication called Danegaptide can protect against vision-threatening damage in Non-Proliferative Diabetic Retinopathy (NPDR), a leading cause of blindness in working-age adults. The study highlights a new therapeutic approach that could replace or complement frequent, invasive eye injections for mill...

SourceTrinity College Dublin·JournalScience Translational Medicine·DateSep 23, 2026